prikaz prve stranice dokumenta Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study
  Download
PDF 1.54 MB
Scientific paper - Original scientific paper
Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study
Cancers, 14 (2022), 11; 2688. https://doi.org/10.3390/cancers14112688
Kaučić, Hrvoje; Kosmina, Domagoj; Schwarz, Dragan; Mack, Andreas; Šobat, Hrvoje; Čehobašić, Adlan; Leipold, Vanda; Andrašek, Iva; Avdičević, Asmir; Mlinarić, Mihaela

Cite this document

Kaučić, H., Kosmina, D., Schwarz, D., Mack, A., Šobat, H., Čehobašić, A. ... Mlinarić, M. (2022). Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study. Cancers, 14. (11). doi: 10.3390/cancers14112688

Kaučić, Hrvoje, et al. "Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study." Cancers, vol. 14, no. 11, 2022. https://doi.org/10.3390/cancers14112688

Kaučić, Hrvoje, Domagoj Kosmina, Dragan Schwarz, Andreas Mack, Hrvoje Šobat, Adlan Čehobašić, Vanda Leipold, Iva Andrašek, Asmir Avdičević and Mihaela Mlinarić. "Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study." Cancers 14, no. 11 (2022). https://doi.org/10.3390/cancers14112688

Kaučić, H., et al. (2022) 'Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study', Cancers, 14(11). doi: 10.3390/cancers14112688

Kaučić H, Kosmina D, Schwarz D, Mack A, Šobat H, Čehobašić A, and sur.. Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study. Cancers [Internet]. 2022 May 29 [cited 2024 November 30];14(11). doi: 10.3390/cancers14112688

H. Kaučić, et al., "Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study", Cancers, vol. 14, no. 11, May 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:053459. [Accessed: 30 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study
AuthorHrvoje Kaučić
AuthorDomagoj Kosmina
AuthorDragan Schwarz
AuthorAndreas Mack
AuthorHrvoje Šobat
AuthorAdlan Čehobašić
AuthorVanda Leipold
AuthorIva Andrašek
AuthorAsmir Avdičević
AuthorMihaela Mlinarić
Author's institutionUniversity of Rijeka
Faculty of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Radiotherapy and Oncology
Abstract (english)
(1) Background: The aim of this study was to evaluate the efficacy and safety of SABR for LAPC using Calypso® Extracranial Tracking for intrafractional, fiducial-based motion management, to present this motion management technique, as there are yet no published data on usage of Calypso® during SABR for LAPC, and to report on our clinical outcomes. (2) Methods: Fifty-four patients were treated with SABR in one, three, or five fractions, receiving median BED10 = 112.5 Gy. Thirty-eight patients received systemic treatment. End points were OS, FFLP, PFS, and toxicity. Actuarial survival analysis and univariate analysis were investigated. (3) Results: Median follow-up was 20 months. Median OS was 24 months. One-year FFLP and one-year OS were 100% and 90.7%, respectively. Median PFS was 18 months, and one-year PFS was 72.2%. Twenty-five patients (46.3%) were alive at the time of analysis, and both median FU and OS for this subgroup were 26 months. No acute/late toxicity > G2 was reported. (4) Conclusions: SABR for LAPC using Calypso® presented as an effective and safe treatment and could be a promising local therapeutic option with very acceptable toxicity, either as a single treatment or in a multimodality regimen. Dose escalation to the tumor combined with systemic treatment could yield better clinical outcomes.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleCancers
Numberingvol. 14, no. 11, 2688
e-ISSN2072-6694
DOIhttps://doi.org/10.3390/cancers14112688
URN:NBNurn:nbn:hr:184:053459
Publication2022-05-29
Document URLhttps://www.mdpi.com/2072-6694/14/11/2688
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2022-10-18 11:50:11